🇺🇸 FDA
Pipeline program

Dapagliflozin 10 mg

D1693C00001

Phase 3 small_molecule completed

Quick answer

Dapagliflozin 10 mg for Diabetes Mellitus, Non-Insulin-Dependent is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Diabetes Mellitus, Non-Insulin-Dependent
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials